Florian Ingelfinger
Overview
Explore the profile of Florian Ingelfinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
971
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodov A, Baniadam H, Zeiser R, Amit I, Yosef N, Wertheimer T, et al.
Eur J Immunol
. 2025 Feb;
55(2):e202451234.
PMID: 39964048
Recent advances in multi-omics and spatially resolved single-cell technologies have revolutionised our ability to profile millions of cellular states, offering unprecedented opportunities to understand the complex molecular landscapes of human...
2.
DAvanzo C, Blaeschke F, Lysandrou M, Ingelfinger F, Zeiser R
Trends Pharmacol Sci
. 2024 Nov;
45(12):1119-1134.
PMID: 39603960
Cell-based therapies harness the endogenous ability of the immune system to fight cancer and have shown promising results in the treatment of hematological malignancies. However, their clinical application beyond B...
3.
4.
Ingelfinger F, Kuiper K, Ulutekin C, Rindlisbacher L, Mundt S, Gerdes L, et al.
Med
. 2024 Mar;
5(4):368-373.e3.
PMID: 38531361
Background: In multiple sclerosis (MS), B cells are considered main triggers of the disease, likely as the result of complex interaction between genetic and environmental risk factors. Studies on monozygotic...
5.
Wertheimer T, Zwicky P, Rindlisbacher L, Sparano C, Vermeer M, Silva de Melo B, et al.
Nat Immunol
. 2024 Feb;
25(3):512-524.
PMID: 38356059
Interleukin-23 (IL-23) is a proinflammatory cytokine mainly produced by myeloid cells that promotes tumor growth in various preclinical cancer models and correlates with adverse outcomes. However, as to how IL-23...
6.
Kirschenbaum D, Xie K, Ingelfinger F, Katzenelenbogen Y, Abadie K, Look T, et al.
Cell
. 2023 Dec;
187(1):149-165.e23.
PMID: 38134933
Deciphering the cell-state transitions underlying immune adaptation across time is fundamental for advancing biology. Empirical in vivo genomic technologies that capture cellular dynamics are currently lacking. We present Zman-seq, a...
7.
Ulutekin C, Galli E, Schreiner B, Khademi M, Callegari I, Piehl F, et al.
Cell Rep Med
. 2023 Dec;
5(1):101351.
PMID: 38134930
Multiple sclerosis is a chronic inflammatory disease of the central nervous system. Whereas T cells are likely the main drivers of disease development, the striking efficacy of B cell-depleting therapies...
8.
Andreadou M, Ingelfinger F, De Feo D, Cramer T, Tuzlak S, Friebel E, et al.
Nat Neurosci
. 2023 Sep;
26(10):1701-1712.
PMID: 37749256
Interleukin-12 (IL-12) is a potent driver of type 1 immunity. Paradoxically, in autoimmune conditions, including of the CNS, IL-12 reduces inflammation. The underlying mechanism behind these opposing properties and the...
9.
Krishnarajah S, Ingelfinger F, Friebel E, Cansever D, Amorim A, Andreadou M, et al.
Nat Aging
. 2023 Apr;
2(1):74-89.
PMID: 37118354
Aging exerts profound and paradoxical effects on the immune system, at once impairing proliferation, cytotoxicity and phagocytosis, and inducing chronic inflammation. Previous studies have focused on individual tissues or cell...
10.
Gonzalo Nunez N, Schmid J, Power L, Alberti C, Krishnarajah S, Kreutmair S, et al.
Nat Immunol
. 2023 Apr;
24(6):941-954.
PMID: 37095378
The range of vaccines developed against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) provides a unique opportunity to study immunization across different platforms. In a single-center cohort, we analyzed the...